Uncategorized
Presbia set to complete second stage enrollment for presbyopic lens
BARCELONA — Presbia announced here that it has scheduled final surgeries for implanting the Flexivue MicroLens, which will complete the second stage of enrollment for the FDA pivotal study.In February 2015, the FDA gave Presbia approval to begin the second stage study of the hydrophilic corneal inlay that is implanted in the non-dominant eye for the correction of presbyopia. The lens has a power range of 1.5 D to 3.5 D and is placed in a pocket created by a femtosecond laser.